Biogen Inc. Sample Contracts

EXHIBIT 99.2 Published CUSIP Number: [________________] CREDIT AGREEMENT Dated as of June 29, 2007
Credit Agreement • July 2nd, 2007 • Biogen Idec Inc. • Biological products, (no disgnostic substances) • New York
AutoNDA by SimpleDocs
EXHIBIT 99.1 LOAN AGREEMENT Dated as of June 28, 2007
Loan Agreement • July 2nd, 2007 • Biogen Idec Inc. • Biological products, (no disgnostic substances) • New York
RECITALS:
Lease • March 10th, 2004 • Biogen Idec Inc • Biological products, (no disgnostic substances)
TRUSTEE
Idec Pharmaceuticals Corp / De • March 31st, 1999 • Biological products, (no disgnostic substances) • New York
CREDIT AGREEMENT Dated as of August 28, 2015 among
Credit Agreement • September 1st, 2015 • Biogen Inc. • Biological products, (no disgnostic substances) • New York

This CREDIT AGREEMENT (“Agreement”) is entered into as of August 28, 2015, among BIOGEN INC., a Delaware corporation (the “Borrower”), each lender from time to time party hereto (collectively, the “Lenders” and individually, a “Lender”), the L/C Issuers from time to time party hereto and BANK OF AMERICA, N.A., as Administrative Agent, Swing Line Lender and an L/C Issuer.

BETWEEN
Supply Agreement • November 14th, 2001 • Idec Pharmaceuticals Corp / De • Biological products, (no disgnostic substances) • New York
1 2,000,000 SHARES IDEC PHARMACEUTICALS CORPORATION COMMON STOCK, $.001 PAR VALUE UNDERWRITING AGREEMENT
Idec Pharmaceuticals Corp / De • February 24th, 1998 • Biological products, (no disgnostic substances) • New York
Amended and Restated Rights Agreement Dated as of July 26, 2001
Rights Agreement • July 27th, 2001 • Idec Pharmaceuticals Corp / De • Biological products, (no disgnostic substances) • Delaware
AND
License Agreement • August 16th, 1999 • Idec Pharmaceuticals Corp / De • Biological products, (no disgnostic substances)
AGREEMENT AND PLAN OF MERGER by and among REATA PHARMACEUTICALS, INC., BIOGEN INC. and RIVER ACQUISITION, INC. Dated as of July 28, 2023
Agreement and Plan of Merger • July 31st, 2023 • Biogen Inc. • Biological products, (no disgnostic substances) • Delaware

THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of July 28, 2023, by and among Biogen Inc., a Delaware corporation (“Parent”), River Acquisition, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub”), and Reata Pharmaceuticals, Inc., a Delaware corporation (the “Company”).

Biogen Idec Inc. Underwriting Agreement
Underwriting Agreement • March 4th, 2008 • Biogen Idec Inc. • Biological products, (no disgnostic substances)

Goldman, Sachs & Co. Merrill Lynch & Co. Merrill Lynch, Pierce, Fenner & Smith Incorporated As representatives of the several Underwriters named in Schedule I hereto,

CREDIT AGREEMENT Dated as of January 28, 2020 among BIOGEN INC., as the Borrower, BANK OF AMERICA, N.A., as Administrative Agent, Swing Line Lender and the L/C Issuer, CITIBANK, N.A., DEUTSCHE BANK AG, NEW YORK BRANCH, GOLDMAN SACHS BANK USA, JPMORGAN...
Credit Agreement • February 3rd, 2020 • Biogen Inc. • Biological products, (no disgnostic substances) • New York

This CREDIT AGREEMENT (this “Agreement”) is entered into as of January 28, 2020, among BIOGEN INC., a Delaware corporation (the “Borrower”), each Lender from time to time party hereto, and BANK OF AMERICA, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer.

IDEC PHARMACEUTICALS CORPORATION (a Delaware corporation) ISSUER $300,000,000 Liquid Yield Option Notes(TM) due 2019 (Zero Coupon -- Subordinated)
Registration Rights Agreement • March 31st, 1999 • Idec Pharmaceuticals Corp / De • Biological products, (no disgnostic substances) • New York
BACKGROUND
Agreement • August 14th, 1997 • Idec Pharmaceuticals Corp / De • Biological products, (no disgnostic substances) • New York
AMENDMENT TO CREDIT AGREEMENT
Credit Agreement • February 15th, 2023 • Biogen Inc. • Biological products, (no disgnostic substances) • New York

This CREDIT AGREEMENT (this “Agreement”) is entered into as of January 28, 2020, among BIOGEN INC., a Delaware corporation (the “Borrower”), each Lender from time to time party hereto, and BANK OF AMERICA, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer.

AutoNDA by SimpleDocs
and
Rights Agreement • August 1st, 1997 • Idec Pharmaceuticals Corp / De • Biological products, (no disgnostic substances) • Delaware
BETWEEN
Collaborative Research and License Agreement • March 30th, 2000 • Idec Pharmaceuticals Corp / De • Biological products, (no disgnostic substances) • California
BIOGEN INC. and U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Debt Securities Dated as of September 15, 2015
Biogen Inc. • September 16th, 2015 • Biological products, (no disgnostic substances) • New York

INDENTURE, dated as of September 15, 2015, by and between Biogen Inc., a Delaware corporation, as Issuer (the “Company”), and U.S. Bank National Association, a national association, as Trustee (the “Trustee”).

Biogen Inc.
Biogen Inc. • April 30th, 2020 • Biological products, (no disgnostic substances) • New York

Biogen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to Goldman Sachs & Co. LLC, BofA Securities, Inc., J.P. Morgan Securities LLC and each of the other Underwriters named in Schedule I hereto (the “Underwriters”), for whom Goldman Sachs & Co. LLC, BofA Securities, Inc. and J.P. Morgan Securities LLC are acting as representatives (in such capacity, the “Representatives”), the respective amounts set forth in Schedule I of $1,500,000,000 aggregate principal amount of the Company’s 2.250% Senior Notes due 2030 (the “2030 Notes”) and $1,500,000,000 aggregate principal amount of the Company’s 3.150% Senior Notes due 2050 (the “2050 Notes” and, together with the 2030 Notes, the “Securities”).

TERM LOAN CREDIT AGREEMENT Dated as of August 28, 2023 among BIOGEN INC., as the Borrower, JPMORGAN CHASE BANK, N.A., as Administrative Agent and The Other Lenders Party Hereto JPMORGAN CHASE BANK, N.A., BANK OF AMERICA, N.A., BANK OF CHINA, NEW YORK...
Term Loan Credit Agreement • September 1st, 2023 • Biogen Inc. • Biological products, (no disgnostic substances) • Delaware

This TERM LOAN CREDIT AGREEMENT (this “Agreement”) is entered into as of August 28, 2023, among BIOGEN INC., a Delaware corporation (the “Borrower”), each Lender from time to time party hereto, and JPMORGAN CHASE BANK, N.A., as Administrative Agent.

BACKGROUND
Collaborative Development Agreement • November 14th, 2001 • Idec Pharmaceuticals Corp / De • Biological products, (no disgnostic substances) • California
SEPARATION AGREEMENT by and between BIOGEN INC. and BIOVERATIV INC. Dated as of January 31, 2017
Separation Agreement • February 2nd, 2017 • Biogen Inc. • Biological products, (no disgnostic substances) • Delaware

This SEPARATION AGREEMENT (this “Agreement”), dated as of January 31, 2017, is entered into by and between Biogen Inc. (“Biogen”), a Delaware corporation, and Bioverativ Inc. (“Bioverativ”), a Delaware corporation and a wholly owned subsidiary of Biogen. “Party” or “Parties” means Biogen or Bioverativ, individually or collectively, as the case may be. Each capitalized term used and not elsewhere defined herein has the meaning set forth in Section 1.1.

COMMON STOCK (PAR VALUE $.0005 PER SHARE)
Intersyndicate Agreement • November 9th, 2000 • Idec Pharmaceuticals Corp / De • Biological products, (no disgnostic substances) • New York
VOTING AND SUPPORT AGREEMENT
Voting and Support Agreement • July 31st, 2023 • Biogen Inc. • Biological products, (no disgnostic substances) • Delaware

THIS VOTING AND SUPPORT AGREEMENT is dated as of July 28, 2023 (this “Agreement”), by and among each stockholder of Reata Pharmaceuticals, Inc., a Delaware corporation (the “Company”), set forth on Exhibit A hereto (each a “Holder” and collectively the “Holders”), Biogen Inc., a Delaware corporation (“Parent”), and River Acquisition, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”).

SETTLEMENT AND LICENSE AGREEMENT among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma A/S and Each of the Parties Listed on Appendix I Dated as of January 17, 2017
Settlement and License Agreement • February 1st, 2017 • Biogen Inc. • Biological products, (no disgnostic substances) • New York

SETTLEMENT AND LICENSE AGREEMENT (this “Agreement”) dated as of the Agreement Date (as defined below), among each of the following Parties:

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!